| 货号 | 18508-100mg |
| 描述 | Hydroxytacrine is a bioactive monohydroxylated metabolite of the cholinesterase inhibitor, tacrine (Item No. 70240), produced by cytochrome P450 1A-catalyzed hydroxylation.1 While tacrine has been used clinically in the treatment of Alzheimer’s disease, its prolonged use is associated with liver toxicity.2,3 Hydroxytacrine demonstrates similar anticholinesterase activity to tacrine, yet has less acute toxicity in both animal and clinical studies of Alzheimer’s disease.4,5 |
| 别名 | HP 029;1-Hydroxytacrine;P 83-6029A;Velnacrine; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Peng, J.Z.,Remmel, R.P., and Sawchuk, R.J. Inhibition of murine cytochrome P4501A by tacrine: In vitro studies. Drug Metabolism and Disposition 32(8), 805-812 (2004). 2.Muñoz-Torrero, D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s disease. Curr. Med. Chem. 15, 2433-2455 (2008). 3.Giacobini, E. Cholinesterase inhibitors for Alzheimer’s disease therapy: From tacrine to future applications. Neurochemistry International 32, 413-419 (1998). 4.Shutske, G.M.,Pierrat, F.A.,Cornfeldt, M.L., et al. (±)9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer’s disease therapeutic of low toxicity. Journal of Medicinal Chemistry 31(7), 1278-1279 (1988). 5.Braga, M.F.M.,Harvey, A.L., and Rowan, E.G. Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro. British Journal of Pharmacology 102(4), 909-915 (1991). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 330.3 |
| 分子式 | C13H14N2O • C4H4O4 |
| CAS号 | 118909-22-1 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |